Pay in 4 interest-free payments of $5.48 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Tirzepatide (Mounjaro) is a dual GIP and GLP-1 receptor agonist licensed in the UK for type 2 diabetes and weight management in adults with obesity or overweight with comorbidities
Its skin-lightening effect was detected incidentally
The significant SOCs that met four criteria were gastrointestinal disorders, metabolism and nutrition disorders and hepatobiliary disorders
*Correspondence: Youxin Chen, [email protected] These authors have contributed equally to this work and share first authorship Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
US$ 29.74
US$ 27.24
US$ 29.74
US$ 23.26
US$ 24.37
